Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from MacroGenics ( (MGNX) ) is now available.
On February 23, 2026, MacroGenics announced that the U.S. Food and Drug Administration placed a partial clinical hold on its Phase 2 LINNET trial of lorigerlimab, a bispecific DART molecule targeting PD-1 and CTLA-4, in patients with gynecologic cancers. Under the hold, enrollment of new participants is paused, though the 41 patients already dosed in the platinum-resistant ovarian and clear cell gynecologic cancer cohorts may continue receiving treatment.
The FDA action followed MacroGenics’ own temporary enrollment pause after serious safety events across four patients, including Grade 4 thrombocytopenia, myocarditis, neutropenia with septic shock, and one resulting Grade 5 event. The move highlights heightened regulatory scrutiny around lorigerlimab’s safety profile and injects uncertainty into the development timeline of a key oncology asset for MacroGenics and its stakeholders.
The most recent analyst rating on (MGNX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on MacroGenics stock, see the MGNX Stock Forecast page.
Spark’s Take on MGNX Stock
According to Spark, TipRanks’ AI Analyst, MGNX is a Neutral.
The score is primarily held down by weak financial performance (declining revenue, large ongoing losses, and significant cash burn that increases financing risk). Technicals provide some offset with recent positive momentum and price strength versus moving averages, but signals are nearing overbought. Valuation remains unattractive due to negative earnings, and a negative corporate event (CMO departure) adds execution risk.
To see Spark’s full report on MGNX stock, click here.
More about MacroGenics
MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The company leverages proprietary next-generation antibody technology platforms and protein engineering expertise to build its pipeline and has entered into multiple strategic collaborations with global pharmaceutical and biotechnology partners.
Average Trading Volume: 1,262,995
Technical Sentiment Signal: Sell
Current Market Cap: $107.5M
Learn more about MGNX stock on TipRanks’ Stock Analysis page.